Multiple Sclerosis

Investigators will test whether adding anodal transcranial direct current stimulation to exergame-based rehabilitation improves short- and long-term cognitive outcomes in 80 adults with multiple sclerosis.

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

New research comparing the safety profiles of the 2 multiple sclerosis therapies suggests ocrelizumab is associated with lower rates of all-cause hospitalization and hypogammaglobulinemia.

Diet and wellness impact multiple sclerosis management, enhancing quality of life and reducing fatigue through lifestyle changes and holistic approaches.

Explore how the Veteran Affairs (VA) MS Centers of Excellence enhance veteran care through a hub-and-spoke model, telehealth, and groundbreaking research.

Diet and metabolic health may have causal effects on MS development, suggesting that a healthy weight, controlling glucose levels, and reducing red meat intake may delay or prevent onset.

Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression.

The study underscores the importance of repeat testing in cases where myelin oligodendrocyte glycoprotein immunoglobulin G tests are borderline.

Radiomic assessment has been used to distinguish multiple sclerosis from similar disorders, and it might also be useful in identifying MS stages and subtypes.

Structural and microbial findings point to a potential nasal-brain immune connection in patients with multiple sclerosis (MS).

Lesion-based disconnectome mapping suggests that the pattern, not the quantity, of brain damage determines cognitive outcomes in patients with MS.

Researchers developed a first-of-its-kind panel to track receptor expression and predict therapy response.

New research reveals that changes in normal-appearing white and gray matter significantly impact MS progression, challenging traditional lesion-focused views.

Iron dysregulation significantly impacts multiple sclerosis progression, linking iron levels to neuroinflammation, demyelination, and potential therapeutic strategies.

Discover how biomarkers like neurofilament light chain and glial fibrillary acidic protein enhance personalized care for patients who have multiple sclerosis.

Navigating treatment for multiple sclerosis and comorbid inflammatory diseases presents unique challenges, requiring careful, interdisciplinary strategies for optimal patient care.

Research highlights a strong link between Epstein-Barr virus and multiple sclerosis (MS), suggesting new therapeutic strategies targeting the virus for MS treatment.

A recent study reveals that over one-third of individuals with relapsing-remitting multiple sclerosis (MS) do not fully recover from relapses, highlighting critical recovery factors.

A study reveals that nearly 80% of US neurologists prescribing multiple sclerosis (MS) therapies received industry payments, influencing their prescribing patterns significantly.

New insights reveal how early intervention in radiologically isolated syndrome can delay multiple sclerosis (MS) onset and improve patient outcomes.

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) disease activity.

Real-world studies reveal limited insights on infection risks for multiple sclerosis patients using disease-modifying treatments, highlighting gaps in clinical trial data.

Panelists discuss how providers and payers must collaborate to develop innovative coverage criteria for BTK inhibitors that prevent patients with subclinical progression from being forced to fail multiple inappropriate therapies before accessing optimal treatment.

Innovative therapies, including BTK inhibitors, target multiple sclerosis progression, offering hope for improved treatment outcomes and myelin repair.

Panelists discuss how academic centers can use telehealth programs like Project ECHO to train community neurologists and ensure consistent, evidence-based MS care across diverse geographic regions.